Kyverna Therapeutics (NASDAQ:KYTX – Get Free Report) and Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, dividends, analyst recommendations, institutional ownership, valuation and profitability.
Institutional & Insider Ownership
18.1% of Kyverna Therapeutics shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 8.8% of Aligos Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Valuation & Earnings
This table compares Kyverna Therapeutics and Aligos Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Kyverna Therapeutics | $7.03 million | 32.65 | -$60.37 million | N/A | N/A |
| Aligos Therapeutics | $7.97 million | 3.92 | -$87.68 million | ($20.50) | -0.48 |
Analyst Ratings
This is a breakdown of current ratings and price targets for Kyverna Therapeutics and Aligos Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Kyverna Therapeutics | 0 | 1 | 7 | 1 | 3.00 |
| Aligos Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Kyverna Therapeutics currently has a consensus target price of $28.71, indicating a potential upside of 439.74%. Aligos Therapeutics has a consensus target price of $75.00, indicating a potential upside of 667.66%. Given Aligos Therapeutics’ higher possible upside, analysts clearly believe Aligos Therapeutics is more favorable than Kyverna Therapeutics.
Profitability
This table compares Kyverna Therapeutics and Aligos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Kyverna Therapeutics | N/A | N/A | N/A |
| Aligos Therapeutics | -1,100.48% | -110.59% | -63.90% |
Summary
Kyverna Therapeutics beats Aligos Therapeutics on 7 of the 11 factors compared between the two stocks.
About Kyverna Therapeutics
Kyverna Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing cell therapies for patients suffering from autoimmune diseases. Its lead product candidate is KYV-101, an autologous CD19 CAR T-cell product candidate for the treatment of patients with lupus nephritis and systemic sclerosis that is in Phase I clinical trial; and for myasthenia gravis and multiple sclerosis that is in Phase II clinical trial. The company is also developing KYV-201, an allogeneic CD19 CAR T-cell product candidate that is in preclinical stage to treat multiple autoimmune diseases. In addition, it is developing product candidates to treat other autoimmune diseases, such as inflammatory bowel disease that includes Crohn's disease and ulcerative colitis. Kyverna Therapeutics, Inc. has a license and collaboration agreement with Intellia Therapeutics, Inc. to research and develop an allogeneic CD19-directed CAR cell therapy product; and with Kite to research and develop programs for the treatment, diagnosis, and prevention of autoimmune, inflammatory, and allogeneic stem cell transplant inflammatory diseases. The company was formerly known as BAIT Therapeutics, Inc. and changed its name to Kyverna Therapeutics, Inc. in October 2019. Kyverna Therapeutics, Inc. was incorporated in 2018 and is headquartered in Emeryville, California.
About Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Receive News & Ratings for Kyverna Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kyverna Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
